Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

CTNM Contineum Therapeutics Inc

13,09

-0,20 (-1,50%)

Última atualização: 13:10:45

Atrasado em 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/18/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

08/19/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Daniel S. Lorrain

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Contineum Therapeutics (NASDAQ:CTNM)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025

Click aqui para mais gráficos Contineum Therapeutics.

Contineum Therapeutics (NASDAQ:CTNM)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025

Click aqui para mais gráficos Contineum Therapeutics.

Notícias Contineum Therapeutics Inc

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Quarta, 8 de Janeiro de 2025 (5 dias atrás) • Business Wire

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
Segunda, 6 de Janeiro de 2025 (1 semana atrás) • GlobeNewswire Inc.

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
Segunda, 16 de Dezembro de 2024 (4 semanas atrás) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 27 de Novembro de 2024 (2 meses atrás) • Edgar (US Regulatory)

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference
Segunda, 25 de Novembro de 2024 (2 meses atrás) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Quarta, 20 de Novembro de 2024 (2 meses atrás) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Segunda, 18 de Novembro de 2024 (2 meses atrás) • Edgar (US Regulatory)

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain
Segunda, 18 de Novembro de 2024 (2 meses atrás) • Business Wire

Contineum Therapeutics to Attend Upcoming Investor Conferences
Quarta, 13 de Novembro de 2024 (2 meses atrás) • Business Wire

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Quarta, 6 de Novembro de 2024 (2 meses atrás) • Edgar (US Regulatory)

Form 8-K - Current report
Quarta, 6 de Novembro de 2024 (2 meses atrás) • Edgar (US Regulatory)

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Quarta, 6 de Novembro de 2024 (2 meses atrás) • Business Wire

Mais Notícias de Contineum Therapeutics Inc

Índice Bovespa

Aeris Industria E Comerc... ON

Brava Energia ON

PÃO DE AÇUCAR ON

Fictor Alimentos ON

HOTEIS OTHON PN

Fundo Invest Amazonia Fi...

FER HERINGER ON

$Logo da Infracommerce Caxaas ON (IFCM3).$

Infracommerce Caxaas ON

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições